SEMAX 30mg

SEMAX 30mg is a high-purity, research-grade synthetic heptapeptide designed exclusively for in vitro scientific research and laboratory experimentation. Chemically identified as Met-Glu-His-Phe-Pro-Gly-Pro (MEHFPGP), SEMAX is an analog of the adrenocorticotropic hormone (ACTH) fragment 4-10, engineered to eliminate hormonal activity while retaining potent nootropic, neuroprotective, and neurorestorative properties. Developed in the 1980s by the Institute of Molecular Genetics in Russia, SEMAX has been extensively studied for its potential to enhance cognitive function, protect neural tissue, and support recovery in various neurological models. This product is strictly intended for laboratory use by qualified researchers and is not approved for human or animal consumption, medical, cosmetic, or diagnostic purposes outside of regulated jurisdictions.

• Chemical Name: Methionyl-Glutamyl-Histidyl-Phenylalanyl-Prolyl-Glycyl-Proline (Ac-MEHFPGP)
• Molecular Formula: C39H54N10O10S
• Molecular Weight: 854.99 g/mol
• CAS Number: 80714-61-0
• Purity: ≥99% (verified by High-Performance Liquid Chromatography, HPLC)
• Appearance: White to off-white lyophilized powder or gel in a sterile, sealed vial
• Solubility: Soluble in bacteriostatic water or sterile saline for reconstitution
• Stability: Stable for up to 2 years when stored at 2–8°C (refrigerated) in lyophilized form; reconstituted solutions remain stable for up to 30 days under refrigeration when handled aseptically.
• pH (Reconstituted): Approximately 5.5–6.5 in aqueous solution
  SEMAX’s peptide structure is designed for stability under controlled conditions, with an acetylated N-terminus and amidated C-terminus to enhance resistance to enzymatic degradation. Its poor oral bioavailability necessitates intranasal or subcutaneous administration in research settings to achieve optimal blood-brain barrier penetration.

SEMAX 30mg is a versatile peptide for neuroscience and related research, with applications including:

• Cognitive Enhancement: SEMAX has been studied for its ability to improve attention, short-term memory, and operative memory. A 1996 study in Bulletin of Experimental Biology and Medicine reported a 71% correct response rate in healthy subjects performing repetitive tasks under SEMAX (250 µg intranasally) compared to 41% in controls, with effects most pronounced under cognitive stress or fatigue.
• Neuroprotection: SEMAX protects neurons in models of ischemic stroke, global cerebral ischemia, and hypoxic conditions. It reduces cortical nitric oxide (NO) production by 30–40% and mitigates neurological deficits (e.g., seizures, motor impairments) in rat models of middle cerebral artery occlusion.
• Neurorestoration: SEMAX promotes functional recovery post-stroke by upregulating brain-derived neurotrophic factor (BDNF) and nerve growth factor (NGF). A 2018 clinical study in Zh Nevrol Psikhiatr Im S S Korsakova reported a 1.4-fold increase in BDNF levels in stroke patients, correlating with improved motor and cognitive rehabilitation.
• Mood and Stress Regulation: SEMAX exhibits antidepressant-like and anxiolytic-like effects in animal models, potentially via modulation of dopaminergic (D1/D2 receptor activity) and serotonergic (5-HT1A receptor) systems. It also reduces stress-induced liver damage by enhancing protein synthesis and inhibiting cytolysis.
• Immune and Vascular Effects: SEMAX upregulates gene expression of chemokines, immunoglobulins, and vascular growth factors in ischemic brain models, supporting tissue repair and immune modulation.
• Exploratory Applications: Preliminary studies suggest potential in models of ADHD, Alzheimer’s disease, Parkinson’s disease, optic nerve atrophy, and non-proliferative diabetic retinopathy. For example, a 2001 study reported improved visual acuity and electrophysiological retinal function in patients with optic nerve disease.
• Pain and Inflammation: SEMAX inhibits enkephalinase enzymes (IC50 = 10 µM), preserving enkephalins and potentially reducing pain and inflammation in experimental settings.

SEMAX’s multifaceted effects stem from its interaction with multiple biochemical pathways:

• BDNF and TrkB Upregulation: SEMAX rapidly increases BDNF and tropomyosin receptor kinase B (TrkB) expression in the hippocampus. A single intranasal dose (50 µg/kg) in rats elevated BDNF protein levels 1.4-fold and TrkB phosphorylation 1.6-fold within 3 hours, promoting neuroplasticity and neuronal survival.
• Neurotransmitter Modulation: Enhances dopamine and serotonin signaling, increasing extracellular dopamine by 20–30% in striatal regions and serotonin in the hypothalamus, supporting mood, motivation, and cognitive performance.
• Melanocortin Receptor Activity: Acts as a partial agonist or antagonist at melanocortin receptors (MC4 and MC5), influencing neural and behavioral responses without hormonal effects.
• Enkephalin Preservation: Inhibits enkephalin-degrading enzymes, increasing endogenous opioid peptide levels, which may contribute to analgesic and anxiolytic effects.
• Antioxidant and Circulatory Effects: Reduces oxidative stress by lowering NO and reactive oxygen species (ROS) levels, while improving cerebral blood flow in ischemic models.
• Gene Expression: Modulates expression of genes involved in neurogenesis, angiogenesis, and immune response, as evidenced by transcriptomic studies in ischemic rat brains.

• Presentation: 30mg SEMAX per vial, supplied as lyophilized powder or gel in a sterile, borosilicate glass vial with a rubber stopper and aluminum seal.
• Packaging: Vials are vacuum-sealed and shipped with ice packs to maintain stability during transit (ice may melt during shipping but does not affect product integrity if stored promptly).
• Manufacturing: Produced in a Good Manufacturing Practice (GMP)-compliant facility, free of fillers (e.g., mannitol, dextrose) to ensure maximum purity.
• Storage Conditions:
  • Lyophilized: Store at 2–8°C (refrigerated) or -20°C for long-term storage (up to 2 years). Avoid repeated freeze-thaw cycles.
  • Reconstituted: Stable for up to 30 days at 2–8°C when prepared with bacteriostatic water (0.9% benzyl alcohol). Do not freeze reconstituted solutions.
• Reconstitution: Requires 1–2 mL bacteriostatic water or sterile saline (not included). Gently swirl to dissolve; avoid vigorous shaking to prevent peptide degradation.
• Administration Routes: Commonly studied via intranasal (nasal spray/drops) or subcutaneous injection in animal models. Intranasal administration achieves peak cerebrospinal fluid concentrations within 15–20 minutes due to direct blood-brain barrier access.
• Dosage Guidelines:
  • Animal Models: Typical doses range from 0.015–0.5 mg/kg (intranasal or subcutaneous).
  • Human Studies (Historical): Doses of 200–600 µg/day (intranasal) have been explored for cognitive enhancement or stroke recovery in Russian clinical trials.
  • Always follow institutional protocols and ethical guidelines for dosage determination.
• Shelf Life: 2 years from manufacture date when stored properly (see batch-specific Certificate of Analysis).

• Purity Testing: Each batch undergoes HPLC and mass spectrometry to confirm ≥99% purity, with no detectable endotoxins or microbial contaminants.
• Certificate of Analysis (CoA): Available upon request, detailing purity, molecular weight, and batch-specific data.
• Sterility: Vials are sterilized and packaged under aseptic conditions to ensure suitability for sensitive research applications.
• Quality Indicators: Authentic SEMAX is odorless and colorless when reconstituted. Signs of contamination (e.g., foul odor, black particles, cloudiness) indicate improper storage or manufacturing issues; discard such products immediately.

SEMAX 30mg is designated for in vitro research by trained professionals in controlled laboratory settings. Key safety considerations include:

• Intended Use: Not for human or animal consumption, medical, cosmetic, or diagnostic purposes. In the US, UK, and Australia, SEMAX is not FDA-approved or TGA-approved and is restricted to research.
• Handling: Use sterile gloves, syringes, and equipment to prevent contamination. Follow biosafety level 1 (BSL-1) protocols unless otherwise specified.
• Storage Precautions: Protect from light, heat, and moisture. Avoid shaking reconstituted solutions, as mechanical stress may denature the peptide.
• Potential Research Observations: Studies report mild side effects in experimental settings, including nasal irritation (intranasal administration), transient headaches, or restlessness at high doses. No significant toxicity has been observed at standard research doses.
• Disposal: Dispose of unused or contaminated product in accordance with local biohazard regulations.
• Legal Compliance: Researchers must comply with all applicable regulations in their jurisdiction, including DEA, FDA, or equivalent guidelines for controlled substances or research chemicals.

SEMAX 30mg is sold exclusively for scientific research and development purposes. It is not intended for human or animal use, nor as a drug, supplement, or cosmetic. Improper use may result in adverse effects, and researchers assume full responsibility for compliance with local laws. For detailed safety information, refer to the supplier-provided Safety Data Sheet (SDS). xAI and its affiliates are not liable for misuse of this product.